CNTB News and Press, Connect Biopharma Holdings Limited From 05/20/25

– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which...

2025-05-15 09:10:21 ET More on Connect Biopharma Connect Biopharma receives Nasdaq non-compliance notice Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Biopharma ...

Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 study supporting potential of ra...

– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on tran...

– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Na...

– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan for rademikibart; expect to initiate parallel Phase 2 trials in 2Q25 ȁ...

2025-04-15 18:49:03 ET Connect Biopharma Holdings Limited (CNTB) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.67%. The average open to low on the day of earnings was -6.14%. The ave...

2025-04-15 18:44:03 ET Connect Biopharma Holdings Limited (CNTB) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CNTB stock price following earnings has averaged ±14.09% , with a media...

United Airlines Holdings Inc. (UAL) is expected to report $0.8 for Q1 2025 Bank First Corporation (BFC) is expected to report $1.62 for Q1 2025 Interactive Brokers Group Inc. (IBKR) is expected to report $1.91 for Q1 2025 Bank of America Corporation (BAC) is expected to report $0.81 f...

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE)...